Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Pituitary adenoma is a common neoplasm of the pituitary gland. Although most pituitary adenomas are benign, they can pose significant challenges in terms of their consequences and prognosis due to their tendency to invade surrounding tissues and their effects on hormone secretion. The management of pituitary adenomas typically involves surgery, medical therapy, and radiotherapy, each of which has its own limitations. Mitochondria play a crucial role in tumor development and progression by regulating various metabolic processes and signaling pathways within tumor cells and the tumor microenvironment. Multiple studies have indicated that mitochondrial dysfunction is implicated in human pituitary adenomas. Furthermore, several compounds with therapeutic effects on pituitary adenomas have been reported to target mitochondrial function. In this review, we summarize recent studies that highlight the involvement of mitochondrial homeostasis imbalance in the biology of pituitary adenomas. We conclude that mitochondria may represent a promising therapeutic target for the treatment of pituitary adenomas.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11727349PMC
http://dx.doi.org/10.3390/antiox13121514DOI Listing

Publication Analysis

Top Keywords

pituitary adenomas
24
pituitary
9
pituitary adenoma
8
adenomas
6
genetic functional
4
functional changes
4
changes mitochondria
4
mitochondria pituitary
4
adenoma pathogenesis
4
pathogenesis therapy
4

Similar Publications

Background: Cortisol and growth hormone are important for sleep regulation and cognition. Sleep is critical for cognitive functioning, and memory consolidation. Patients with pituitary disease experience hormonal dysregulation, impaired sleep quality, and cognitive dysfunction.

View Article and Find Full Text PDF

Objective: Pituitary adenomas (PAs) are one of the three major lesions in Multiple Endocrine Neoplasia type 1 (MEN1), with a prevalence of 32 to 58%, yet their specific risk factors remain unidentified. This study aimed to identify predictors influencing PA occurrence in MEN1.

Methods: This nationwide, multicenter, retrospective cohort study involved 240 MEN1 patients, 55.

View Article and Find Full Text PDF

Introduction: Pituitary adenomas (PAs) are generally benign neoplasms, though in rare cases may exhibit aggressive behavior. In 2024, the PANOMEN-3 workshop released a new clinical-pathological classification. The objective of this study was to examine the potential of the PANOMEN-3 classification to predict prognosis of PAs and guide treatment in our single center cohort of patients with PAs.

View Article and Find Full Text PDF

Glucose metabolism alterations are frequently observed in patients with secretory pituitary adenomas. The most commonly secreted hormones in these tumors include prolactin, growth hormone (GH), adrenocorticotropic hormone (ACTH), and thyroid-stimulating hormone (TSH), all of which can disrupt glucose homeostasis through distinct pathophysiological mechanisms. Prolactin stimulates pancreatic β-cell proliferation, enhances insulin gene transcription, increases intracellular insulin content, and augments glucose-induced insulin secretion.

View Article and Find Full Text PDF

Identifying Hub Genes Associated with Sex Disparities in Prolactinomas.

Genet Test Mol Biomarkers

September 2025

Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

Male patients with prolactinomas exhibit greater invasiveness, resistance to dopamine agonists, making treatment more challenging. This study aims to explore the potential different genes contributing to sex disparities in prolactinomas. Weighted gene co-expression network analysis and differential expressed genes analysis were performed to identify sex-related hub genes.

View Article and Find Full Text PDF